Dysregulation of TGF-ß signaling occurs in many cancer subtypes. Preclinical studies of the TGF-ßR1 inhibitor LY3200882 have suggested that this agent may translate well to the clinic. To this end, Yap and colleagues conducted a first-in-human phase I study of LY3200882 in patients with advanced cancer. LY3200882 was well tolerated as monotherap. and in combination with other agents. When combined with gemcitabine and nab-paclitaxel in patients with treatment-naïve pancreatic adenocarcinoma, LY3200882 led to a RECIST v1.1 partial response in 6/12 patients and stable disease in 3/12 patients, an overall disease control rate of 75%. Encouraging response data was observed in patients with grade 4 glioma as well. These results are encouraging and suggest that further clinical assessment of LY3200882 is warranted, especially in patients with pancreatic adenocarcinoma.

cfDNA assays are now approved companion diagnostic tests to identify BRCA+ mCRPC patients for PARP inhibitor therapy. To investigate the clinical impact of...

You do not currently have access to this content.